VBI Vaccines Inc. [NASDAQ: VBIV] traded at a high on 11/11/20, posting a 13.02 gain after which it closed the day’ session at $2.43. The company report on November 9, 2020 that VBI Vaccines Announces e-Poster Presentation at the Society for Neuro-Oncology (SNO) 2020 Virtual Meeting.
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that its abstract highlighting data from Part B of the ongoing Phase 1/2a study of VBI-1901, the Company’s cancer vaccine immunotherapeutic candidate, in recurrent glioblastoma (GBM) was accepted for e-poster presentation at the 25th Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO), taking place November 19-21, 2020.
The results of the trading session contributed to over 13377863 shares changing hands. Over the past one week, the price volatility of VBI Vaccines Inc. stands at 10.15% while the volatility over the past one month is 8.35%.
The market cap for VBIV stock reached $561.81 million, with 231.20 million shares outstanding and 161.74 million shares in the current float. Compared to the average trading volume of 9.68M shares, VBIV reached a trading volume of 13377863 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about VBI Vaccines Inc. [VBIV]?
Raymond James have made an estimate for VBI Vaccines Inc. shares, keeping their opinion on the stock as Strong Buy, with their previous recommendation back on August 27, 2020. While these analysts kept the previous recommendation, Oppenheimer raised their target price to Outperform. The new note on the price target was released on January 16, 2019, representing the official price target for VBI Vaccines Inc. stock. Previously, the target price had yet another raise to $10, while Canaccord Genuity analysts kept a Buy rating on VBIV stock.
The Average True Range (ATR) for VBI Vaccines Inc. is set at 0.21, with the Price to Sales ratio for VBIV stock in the period of the last 12 months amounting to 381.92. The Price to Book ratio for the last quarter was 3.55.
How has VBIV stock performed recently?
VBI Vaccines Inc. [VBIV] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.95. With this latest performance, VBIV shares dropped by -20.85% in over the last four-week period, additionally plugging by 17.39% over the last 6 months – not to mention a rise of 326.32% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VBIV stock in for the last two-week period is set at 43.56, with the RSI for the last a single of trading hit 48.18, and the three-weeks RSI is set at 43.82 for VBI Vaccines Inc. [VBIV]. The present Moving Average for the last 50 days of trading for this stock 2.89, while it was recorded at 2.33 for the last single week of trading, and 2.47 for the last 200 days.
VBI Vaccines Inc. [VBIV]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and VBI Vaccines Inc. [VBIV] shares currently have an operating margin of -2075.96 and a Gross Margin at -310.09. VBI Vaccines Inc.’s Net Margin is presently recorded at -2467.94.
Return on Total Capital for VBIV is now -42.55, given the latest momentum, and Return on Invested Capital for the company is -54.78. Return on Equity for this stock declined to -58.82, with Return on Assets sitting at -42.20. When it comes to the capital structure of this company, VBI Vaccines Inc. [VBIV] has a Total Debt to Total Equity ratio set at 18.47. Additionally, VBIV Total Debt to Total Capital is recorded at 15.59, with Total Debt to Total Assets ending up at 13.34. Long-Term Debt to Equity for the company is recorded at 0.93, with the Long-Term Debt to Total Capital now at 0.78.
Reflecting on the efficiency of the workforce at the company, VBI Vaccines Inc. [VBIV] managed to generate an average of -$438,504 per employee. Receivables Turnover for the company is 17.28 with a Total Asset Turnover recorded at a value of 0.02.
Earnings analysis for VBI Vaccines Inc. [VBIV]
With the latest financial reports released by the company, VBI Vaccines Inc. posted -0.24/share EPS, while the average EPS was predicted by analysts to be reported at -0.22/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -9.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for VBIV.
Insider trade positions for VBI Vaccines Inc. [VBIV]
There are presently around $278 million, or 46.68% of VBIV stock, in the hands of institutional investors. The top three institutional holders of VBIV stocks are: PERCEPTIVE ADVISORS LLC with ownership of 55,042,465, which is approximately 19.784% of the company’s market cap and around 3.52% of the total institutional ownership; STATE STREET CORP, holding 18,560,288 shares of the stock with an approximate value of $39.91 million in VBIV stocks shares; and BLACKROCK INC., currently with $26.29 million in VBIV stock with ownership of nearly -6.496% of the company’s market capitalization.
Positions in VBI Vaccines Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 71 institutional holders increased their position in VBI Vaccines Inc. [NASDAQ:VBIV] by around 37,311,196 shares. Additionally, 36 investors decreased positions by around 3,003,949 shares, while 9 investors held positions by with 73,934,430 shares. The mentioned changes placed institutional holdings at 114,249,575 shares, according to the latest SEC report filing. VBIV stock had 34 new institutional investments in for a total of 5,400,383 shares, while 9 institutional investors sold positions of 484,434 shares during the same period.